22 research outputs found
Identified proteins
Table S1A: Proteins identified in partially purified MCF-7 (CTRL) cell nuclear extracts.
Table S1B: Proteins identified in partially purified CTAP-ER_ expressing MCF-7 (Sample) cell nuclear extracts.
Table S1C: Proteins specifically identified in partially purified CTAP-ER_ (Sample) vs MCF7 (CTRL) nuclear extracts
Comparison of ER beta interactors after either RNA or AGO2 depletion
Diffentially expressed proteins upon RNAse treatment and AGO2 silencing. In italic are displayed those proteins that do not fit the statistical significance parameters
Molecular Mechanisms of Selective Estrogen Receptor Modulator Activity in Human Breast Cancer Cells: Identification of Novel Nuclear Cofactors of AntiestrogenāERĪ± Complexes by Interaction Proteomics
Estrogen receptor alpha (ERĪ±) is a ligand-activated
transcription
factor that controls key cellular pathways <i>via</i> proteināprotein
interactions involving multiple components of transcriptional coregulator
and signal transduction complexes. Natural and synthetic ERĪ±
ligands are classified as agonists (17Ī²-estradiol/E<sub>2</sub>), selective estrogen receptor modulators (SERMs: Tamoxifen/Tam and
Raloxifene/Ral), and pure antagonists (ICI 182,780-Fulvestrant/ICI),
according to the response they elicit in hormone-responsive cells.
Crystallographic analyses reveal ligand-dependent ERĪ± conformations,
characterized by specific surface docking sites for functional proteināprotein
interactions, whose identification is needed to understand antiestrogen
effects on estrogen target tissues, in particular breast cancer (BC).
Tandem affinity purification (TAP) coupled to mass spectrometry was
applied here to map nuclear ERĪ± interactomes dependent upon
different classes of ligands in hormone-responsive BC cells. Comparative
analyses of agonist (E<sub>2</sub>)- vs antagonist (Tam, Ral or ICI)-bound
ERĪ± interacting proteins reveal significant differences among
ER ligands that relate with their biological activity, identifying
novel functional partners of antiestrogenāERĪ± complexes
in human BC cell nuclei. In particular, the E<sub>2</sub>-dependent
nuclear ERĪ± interactome is different and more complex than those
elicited by Tam, Ral, or ICI, which, in turn, are significantly divergent
from each other, a result that provides clues to explain the pharmacological
specificities of these compounds
Molecular Mechanisms of Selective Estrogen Receptor Modulator Activity in Human Breast Cancer Cells: Identification of Novel Nuclear Cofactors of AntiestrogenāERĪ± Complexes by Interaction Proteomics
Estrogen receptor alpha (ERĪ±) is a ligand-activated
transcription
factor that controls key cellular pathways <i>via</i> proteināprotein
interactions involving multiple components of transcriptional coregulator
and signal transduction complexes. Natural and synthetic ERĪ±
ligands are classified as agonists (17Ī²-estradiol/E<sub>2</sub>), selective estrogen receptor modulators (SERMs: Tamoxifen/Tam and
Raloxifene/Ral), and pure antagonists (ICI 182,780-Fulvestrant/ICI),
according to the response they elicit in hormone-responsive cells.
Crystallographic analyses reveal ligand-dependent ERĪ± conformations,
characterized by specific surface docking sites for functional proteināprotein
interactions, whose identification is needed to understand antiestrogen
effects on estrogen target tissues, in particular breast cancer (BC).
Tandem affinity purification (TAP) coupled to mass spectrometry was
applied here to map nuclear ERĪ± interactomes dependent upon
different classes of ligands in hormone-responsive BC cells. Comparative
analyses of agonist (E<sub>2</sub>)- vs antagonist (Tam, Ral or ICI)-bound
ERĪ± interacting proteins reveal significant differences among
ER ligands that relate with their biological activity, identifying
novel functional partners of antiestrogenāERĪ± complexes
in human BC cell nuclei. In particular, the E<sub>2</sub>-dependent
nuclear ERĪ± interactome is different and more complex than those
elicited by Tam, Ral, or ICI, which, in turn, are significantly divergent
from each other, a result that provides clues to explain the pharmacological
specificities of these compounds
Estrogen responding genes per state.
<p>Among the entire gene set considered in the MCF-7 cell experiment, 1270 also responded in ZR-75.1 cells. These are referred to as common āestrogen-regulated genesā (E2R genes) in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0088485#pone.0088485-Cicatiello1" target="_blank">[4]</a>. āPrimary genesā are their subgroup having a ER transcription factor binding site within 10 kb around the TSS. The figures show how E2R and primary genes are responding across the single-cell states of a six-state model. (<b>A</b>) Fraction of up-regulated and down-regulated E2R genes. (<b>B</b>) Fraction of first-responding E2R genes, i.e., of genes that respond for the first time in a given state. (<b>C</b>) and (<b>D</b>) show the analogous pattern of primary genes.</p
Marker genes in the MCF-7 system.
<p>In each state of a six-state model, genes are ranked by their state-expression fold change with respect to the first state. Here, only the top 50 are shown along with their ranking in the other states. For the top genes of state 2 also the rank assigned considering a maximum fold change criterion over the time course is shown for comparison (separated column). The state-based ranking criterion highlights marker genes which would otherwise pass unnoticed.</p
The number of single-cell states in the MCF-7 response to estrogen.
<p>(<b>A</b>) The mean squared error of the model fit to the microarray data decreases as function of the number of states: as expected, when the number of parameters increases, the quality of the fit improves. (<b>B</b>) The condition number is a measure of the similarity of the transcriptional profiles of the states. It increases as function of the number of states, , highlighting that over-fitting also increases with . A good balance between fit quality and over-fitting must be found. (<b>C</b>) The model posterior probability, derived by a Bayesian approach, has a peak at , which shows that a model with six states strikes a good balance between fit-to-data and model parsimony.</p
The single-cell transition rates in the ZR-75.1 system.
<p>Results of the six-state model for time course data in hormone-starved ZR-75.1 cells responding to estrogen stimulation are shown for comparison with the MCF-7 system of <b>Fig. 3</b>. (<b>A</b>) Cell population dynamics. (<b>B</b>) Rates and mean times of transitions. In ZR-75.1 the response to estrogen is initially one order of magnitude faster than in MCF-7.</p
Fits to gene expression time-course data.
<p>The fit to some key genes, comprising the 11 primary transcription factors identified by Cicatiello et<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0088485#pone.0088485-Cicatiello1" target="_blank">[4]</a> and other important estrogen-responsive genes <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0088485#pone.0088485-Zhu1" target="_blank">[1]</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0088485#pone.0088485-Weisz1" target="_blank">[2]</a>, are shown: black circles represent time-course (standardized) data while green lines represents the gene expression predicted by the six-state model.</p
Additional file 8: Table S5. of The nuclear receptor ERĆĖ engages AGO2 in regulation of gene transcription, RNA splicing and RISC loading
Proteomics analysis of ERĆĖ interactome following AGO2 silencing. Table S5a. Raw data. Table S5b. Nomalized data. Table S5c. Statistically significant changes. Table S5d. Not statistically significant changes. (XLSX 201 kb